The Lancet has published three separate correction notices for articles spanning gastroenterology, global health, and neurology. The corrections, issued between June 17 and June 25, involve changes to online versions of previously published pieces.
A correction to a Seminar on primary sclerosing cholangitis revises a sentence concerning vancomycin-resistant enterococci and updates a citation from the 2022 American Association for the Study of Liver Disease practice guidance. The notice states that the fifth sentence of the fourth paragraph in the Inflammatory bowel disease section was amended.
In a separate correction, a World Report on a $518 million Ebola plan jointly launched by WHO and Africa CDC has had a quote from Ibrahima Socé Fall adjusted. The changes reflect developments that occurred between the interview and the original publication date.
A third notice corrects appendix 1 of a phase 3 trial evaluating cemdisiran siRNA for myasthenia gravis, clarifying the list of NIMBLE Trial Investigators. No other changes to the study's conclusions or data were indicated.
The corrections highlight ongoing editorial diligence in medical publishing but do not alter the core findings or recommendations of the original articles. Readers are directed to consult the updated online versions.